Abstract
The CD79 molecule, encoded by the CD79a and CD79b genes, is a signaling unit of the B-cell receptor complex, which transmits signals of B-cell activation, growth, and differentiation. They are B-cell-specific and expressed at most stages of B-cell development. Although plasma cells have been believed to lack these gene products, the regulation of CD79 expression in plasma cells is still controversial. In particular, the regulation of CD79b expression remains unclear. We sought to examine CD79b expression in normal and neoplastic plasma cells by immunohistochemical analysis. Out of the 23 clinical samples and 11 cell lines of plasma cell myeloma (PCM), none of the clinical samples and only 1 of 11 cell lines expressed CD79b immunohistologically, whereas non-neoplastic plasma cells in reactive hyperplastic lymph nodes exhibited loss of CD79b protein expression. This finding is quite different from our previous report on CD79a. Not only immunocytochemistry, but also RT-PCR and Western blot analysis of PCM cell lines gave identical results. Interestingly, we detected mRNA transcripts of CD79b in PCM cell lines, although protein translation was lacking. These findings suggest that expression of CD79b is downregulated in both plasma cells and plasma cell myeloma, and this process is possibly under post transcriptional regulation.
| Original language | English |
|---|---|
| Pages (from-to) | 122-129 |
| Number of pages | 8 |
| Journal | Pathology International |
| Volume | 61 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2011 |
Fingerprint
Keywords
- B-cell receptor
- CD79a
- CD79b
- Plasma cell
- Plasma cell myeloma
ASJC Scopus subject areas
- Pathology and Forensic Medicine
Cite this
Downregulation of the B-cell receptor signaling component CD79b in plasma cell myeloma : A possible post transcriptional regulation. / Huang, Xingang; Takata, Katsuyoshi; Sato, Yasuharu; Tanaka, Takehiro; Ichimura, Kouichi; Tamura, Maiko; Oka, Takashi; Yoshino, Tadashi.
In: Pathology International, Vol. 61, No. 3, 03.2011, p. 122-129.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Downregulation of the B-cell receptor signaling component CD79b in plasma cell myeloma
T2 - A possible post transcriptional regulation
AU - Huang, Xingang
AU - Takata, Katsuyoshi
AU - Sato, Yasuharu
AU - Tanaka, Takehiro
AU - Ichimura, Kouichi
AU - Tamura, Maiko
AU - Oka, Takashi
AU - Yoshino, Tadashi
PY - 2011/3
Y1 - 2011/3
N2 - The CD79 molecule, encoded by the CD79a and CD79b genes, is a signaling unit of the B-cell receptor complex, which transmits signals of B-cell activation, growth, and differentiation. They are B-cell-specific and expressed at most stages of B-cell development. Although plasma cells have been believed to lack these gene products, the regulation of CD79 expression in plasma cells is still controversial. In particular, the regulation of CD79b expression remains unclear. We sought to examine CD79b expression in normal and neoplastic plasma cells by immunohistochemical analysis. Out of the 23 clinical samples and 11 cell lines of plasma cell myeloma (PCM), none of the clinical samples and only 1 of 11 cell lines expressed CD79b immunohistologically, whereas non-neoplastic plasma cells in reactive hyperplastic lymph nodes exhibited loss of CD79b protein expression. This finding is quite different from our previous report on CD79a. Not only immunocytochemistry, but also RT-PCR and Western blot analysis of PCM cell lines gave identical results. Interestingly, we detected mRNA transcripts of CD79b in PCM cell lines, although protein translation was lacking. These findings suggest that expression of CD79b is downregulated in both plasma cells and plasma cell myeloma, and this process is possibly under post transcriptional regulation.
AB - The CD79 molecule, encoded by the CD79a and CD79b genes, is a signaling unit of the B-cell receptor complex, which transmits signals of B-cell activation, growth, and differentiation. They are B-cell-specific and expressed at most stages of B-cell development. Although plasma cells have been believed to lack these gene products, the regulation of CD79 expression in plasma cells is still controversial. In particular, the regulation of CD79b expression remains unclear. We sought to examine CD79b expression in normal and neoplastic plasma cells by immunohistochemical analysis. Out of the 23 clinical samples and 11 cell lines of plasma cell myeloma (PCM), none of the clinical samples and only 1 of 11 cell lines expressed CD79b immunohistologically, whereas non-neoplastic plasma cells in reactive hyperplastic lymph nodes exhibited loss of CD79b protein expression. This finding is quite different from our previous report on CD79a. Not only immunocytochemistry, but also RT-PCR and Western blot analysis of PCM cell lines gave identical results. Interestingly, we detected mRNA transcripts of CD79b in PCM cell lines, although protein translation was lacking. These findings suggest that expression of CD79b is downregulated in both plasma cells and plasma cell myeloma, and this process is possibly under post transcriptional regulation.
KW - B-cell receptor
KW - CD79a
KW - CD79b
KW - Plasma cell
KW - Plasma cell myeloma
UR - http://www.scopus.com/inward/record.url?scp=79952095089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952095089&partnerID=8YFLogxK
U2 - 10.1111/j.1440-1827.2010.02634.x
DO - 10.1111/j.1440-1827.2010.02634.x
M3 - Article
C2 - 21355953
AN - SCOPUS:79952095089
VL - 61
SP - 122
EP - 129
JO - Pathology International
JF - Pathology International
SN - 1320-5463
IS - 3
ER -